The business model of Insulet Corp revolves around the development and commercialization of innovative medical devices for individuals with diabetes. Insulet is known for its flagship product, the Omnipod Insulin Management System, which is a tubeless insulin pump. This system is designed to provide continuous subcutaneous insulin delivery with customizable insulin plans and improved convenience for users. Insulet Corp focuses on helping diabetes patients manage their condition effectively and ensuring a better quality of life. With their unique and advanced technology, Insulet continues to make significant contributions to the diabetes healthcare industry.

Insulet Corp is primarily active in the healthcare industry, specifically in the medical devices sector.

The main competitors of Insulet Corp in the market are Medtronic plc, Tandem Diabetes Care, Inc., and Dexcom, Inc. These companies operate in the same industry sector and offer similar products and services. Medtronic plc is a multinational medical device company, Tandem Diabetes Care, Inc. specializes in insulin pumps, and Dexcom, Inc. provides continuous glucose monitoring systems. These competitors pose challenges to Insulet Corp in terms of market share and product innovation. Competing with these industry leaders, Insulet Corp strives to differentiate itself through its Omnipod System, a unique tubeless insulin delivery system.

Insulet Corp is a leading medical technology company headquartered in Massachusetts, United States. Founded in 2000, Insulet is focused on improving the lives of individuals with diabetes through the development and manufacturing of innovative insulin delivery systems. The company is renowned for its flagship product, the Omnipod Insulin Management System, which offers patients a unique tubeless and wireless insulin pump experience. Insulet has a rich history of achievement and continuous growth, earning recognition for its dedication to patient-centric solutions. With a strong commitment to advancing diabetes care, Insulet Corp has positioned itself as a trusted and reliable provider in the medical technology industry.

Insulet Corp has achieved several significant milestones in its history. One of the notable achievements is the development and introduction of the Omnipod System, a tubeless insulin delivery system that has revolutionized diabetes management. This innovative product has gained wide acceptance and has positively impacted the lives of many patients. Additionally, Insulet Corp has successfully expanded its global presence, securing regulatory approvals in various countries and establishing partnerships with healthcare providers worldwide. The company has also demonstrated consistent financial growth and market success, solidifying its position as a leader in the diabetes technology industry.

Insulet Corp primarily operates in the United States, Canada, Europe, and the Middle East.

Insulet Corp is a renowned company in the stock market known for its values and corporate philosophy. The company aims to improve the lives of people with diabetes through innovative and reliable technologies. Insulet Corp values patient-centricity by providing user-friendly and discreet products like the Omnipod System. Their corporate philosophy revolves around continuous innovation, teamwork, and a commitment to making a difference in diabetes management. Insulet Corp's vision is to empower individuals with diabetes to live life to the fullest, offering them better control, flexibility, and convenience. With a dedicated focus on diabetes care, Insulet Corp sets itself apart in the market, making it a highly regarded company among investors.

Analysts currently set an average price target of 363.98 USD for the Insulet stock (median: 367.20 USD), implying +121.9 % versus the latest price. The consensus is based on 34 analyst ratings.

Insulet Analyst Price Targets 2026

34 analysts currently rate the Insulet stock: 31 recommend buying, 2 holding and 1 selling. For 2026, analysts expect Insulet to generate revenue of 3.37 B USD and earnings per share of 6.47 USD.

Insulet Analyst Price Targets 2026

Converted at the current exchange rate, the Insulet share trades at 143.79 EUR (164.43 USD).

The Insulet share (PODD) is listed on 5 stock exchanges, including: NASDAQ (PODD), Frankfurt (GOV.F), München (GOV.MU), Düsseldorf (GOV.DU), SIX (Zürich) (GOV.SW).

Insulet Corporation is a company specializing in the development and manufacturing of personalized insulin delivery systems. The company is headquartered in Acton, Massachusetts, USA and was founded in 2000.

The expected revenue of Insulet is 3.37 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Insulet is 464.74 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Insulet is currently 25.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Insulet stock.

The price-to-sales ratio (P/S) of Insulet is currently 3.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Insulet stock.

The Eulerpool Quality Score for Insulet is 6/10.

The ISIN of Insulet is US45784P1012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Insulet is A0MQX8. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Insulet is PODD. The ticker symbol is used to trade Insulet shares on the stock exchange.

Insulet paid dividends every year for the past 0 years.

Insulet is assigned to the 'Health' sector.

The dividends of Insulet are distributed in USD.